A novel small molecule fluorescent probe targeting RORγ and its preparation method and application

By designing small molecule fluorescent probes that bind to the RORγ allosteric site and combining them with fluorescence polarization technology, the problem of insufficient efficacy or safety of existing RORγ allosteric inhibitors has been solved. This has enabled efficient screening and imaging of RORγ allosteric inhibitors and provided a stable method for activity testing.

CN116715676BActive Publication Date: 2024-11-26NANJING UNIV OF TRADITIONAL CHINESE MEDICINE
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202310650831.2
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2023-06-02
Publication Date
2024-11-26
Estimated Expiration
2043-06-02

AI Technical Summary

Technical Problem

Existing RORγ allosteric inhibitors have insufficient efficacy or safety issues, making it difficult to treat psoriasis. There is a lack of effective activity testing methods to discover novel RORγ allosteric inhibitors.

Method used

A series of small molecule fluorescent probes that can bind to RORγ allosteric sites were designed. The activity was tested by fluorescence polarization technology and combined with fluorescence imaging. The RORγ allosteric inhibitor MRL-871 was linked to fluorescein isothiocyanate (FITC) using a specific linking method. The probes were then prepared and applied to high-throughput screening and imaging.

Benefits of technology

It provides specific binding to RORγ allosteric sites, enabling the screening of allosteric binding sites of RORγ ligand binding domains and the evaluation of affinity. It also provides an inexpensive, rapid, and stable activity assay method, guiding the development of RORγ allosteric inhibitors.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN116715676B_ABST
    Figure CN116715676B_ABST
Patent Text Reader

Abstract

The present invention discloses a novel small molecule fluorescent probe targeting RORγ and its preparation method and application. The small molecule fluorescent probe designed by the present invention can bind to the allosteric site of the orphan receptor γ related to the retinoic acid receptor, and can be used as a fluorescent probe for cell imaging or in vivo imaging, so it can be used for high-throughput screening of psoriasis therapeutic drugs targeting RORγ, and has important application value. #imgabs0#
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the technical field of fluorescent probes, and in particular relates to a novel fluorescent compound capable of binding to an allosteric site of an orphan receptor gamma related to a retinoic acid receptor and an application thereof as a fluorescent probe for high-throughput screening and imaging. Background Art

[0002] Psoriasis, commonly known as "psoriasis", is a recurrent, chronic skin disease with characteristic scaly erythema. The success of biologics that inhibit interleukin-17 (IL-17) has demonstrated the important role of IL-17 in psoriasis (Lancet 2021, 397, 1301-1315), but the high price of biologics limits more patients from benefiting from them. Retinoic acid receptor-related orphan receptorγ (RORγ) belongs to the transcription factor nuclear receptor family and is the main regulatory protein of IL-17. Inhibiting RORγ is an effective strategy for the treatment of psoriasis. Like most nuclear receptors, RORγ is structurally composed of a nitrogen-terminal domain (NTD), a DNA-binding domain (DBD), a hinge region (Hinge), a ligand-binding domain (LBD), and a carbon-terminal domain (CTD). Among them, LBD is a key domain for transcriptional regulation, which is composed of twelve α-helices (H1-H12). H12 at the carbon end can recruit co-transcription factors, promote DBD to bind to target genes and regulate downstream gene expression (Int J Mol Sci 2020, 21, 5329-5346). There is a conserved orthosteric binding site inside the LBD of the nuclear receptor family. The binding of endogenous ligands to this site can stabilize the structure of H12, promote its binding with co-transcription factors, and enhance transcription. Although the endogenous ligands of RORγ have not yet been determined, a large number of studies have shown that the use of exogenous small molecules to act on the orthosteric site can affect the conformation of H12, thereby regulating its binding ability with co-transcription factors, thereby inhibiting or activating the transcriptional activity of RORγ. At present, more than 30 RORγ orthosteric inhibitor projects have entered clinical trials, but they have all failed due to insufficient efficacy or safety issues. This may be related to the off-target effect caused by the high conservatism of the orthosteric pocket itself. There is also an allosteric pocket inside RORγ, which is unique to RORγ. Using small molecules to target the allosteric pocket has the advantages of better subtype selectivity (Nat. Commun. 2015, 6, 8833-8843). The development of an accurate, stable and reliable RORγ allosteric site activity test method will help discover novel RORγ allosteric inhibitors and guide their structural optimization to obtain candidate drug molecules with better activity, providing support for the development of psoriasis treatment drugs targeting RORγ.

[0003] Small molecule fluorescent probes are commonly used auxiliary tools in medicinal chemistry and are widely used in activity testing and in vitro and in vivo imaging studies. The RORγ allosteric inhibitor MRL-871 is connected to fluorescein isothiocyanate (FITC) by a specific connection method. The present invention discloses a series of small molecule fluorescent probes that can bind to the RORγ allosteric site, their preparation methods, and their applications in activity testing and in vitro and in vivo imaging. Summary of the invention

[0004] A novel small molecule fluorescent probe targeting RORγ, comprising a compound of the following general formula (I) or a pharmaceutically acceptable salt thereof:

[0005]

[0006] In the general formula (I):

[0007] L stands for L1 L2 L3

[0008] L4 L5 L6

[0009] L7 L8 or L9

[0010] The present invention also provides a method for preparing the RORγ small molecule fluorescent probe, comprising the following steps:

[0011]

[0012] S1: reacting the raw material AI-1 with carbon monoxide and different diamine compounds under the catalytic conditions of base and catalyst at high temperature to obtain the intermediate AI-2-L 1~3,7,8 ;

[0013] Preferably, in step S1, the diamine compound used in the reaction is a diamine protected by mono-tert-butyloxycarbonyl (Boc); the carbon monoxide pressure used is 1 to 3 atmospheres; the organic solvent used in the reaction is one or more of N,N-dimethylformamide (DMF), 1,4-dioxane or tetrahydrofuran (THF); the base used in the reaction is one or more of N,N-diisopropylethylamine (DIPEA) or triethylamine (TEA); the catalyst used in the reaction is one or more of 1,1'-bis(diphenylphosphino)ferrocenepalladium dichloride (Pd(dppf)Cl2), palladium acetate (Pd(OAc)2) or tetrakistriphenylphosphine palladium (Pd(PPh3)4); and the reaction temperature is 80-120°C.

[0014]

[0015] S2: The raw material AI-1 is coupled with a diamine compound using a Buchwald-Hartwig reaction under the conditions of a base, a catalyst, and a ligand to obtain the intermediate AI-2-L 4~6 ;

[0016] Preferably, in step S2, the Buchwald-Hartwig reaction uses a catalyst of Pd2(dba)3, Pd(OAc)2, Pd(Dppf)Cl2, a base of one or more of N,N-diisopropylethylamine (DIPEA) or triethylamine (TEA), cesium carbonate (Cs2CO3), potassium tert-butoxide (t-BuOK), and sodium tert-butoxide (t-BuONa), a ligand of 2-dicyclohexylphospho-2',4',6'-triisopropylbiphenyl (XPhos) or 1,1'-binaphthyl-2,2'-bis(diphenylphosphine) (BINAP), and a solvent of 1,4-dioxane.

[0017]

[0018] S3: The raw material AI-1 and 2-(7-octyne-1-yl)-1H-isoindole-1,3-dione are coupled by Sonogashira reaction under base and catalyst conditions to obtain intermediate AI-L9;

[0019] Preferably, in step S3, the catalyst used in the Sonogashira reaction is Pd2(dba)3, Pd(OAc)2, Pd(dppf)Cl2 and CuI, and the organic solvent used is one or more of N,N-diisopropylethylamine (DIPEA) or triethylamine (TEA).

[0020]

[0021] S4: dissolving raw materials AI-2-L1~8 in dichloromethane, reacting at room temperature under acidic conditions, removing tert-butyloxycarbonyl (Boc) to obtain compounds AI-3-L1~8;

[0022] Preferably, in step S4, the acidic reagent is trifluoroacetic acid or dioxane hydrochloride solution.

[0023]

[0024] S5: The intermediate AI-2-L9 is reacted with hydrazine hydrate in ethanol under reflux to remove the protecting group to obtain compound AI-3-L9.

[0025]

[0026] S6: The intermediates AI-3-L1-9 are subjected to a condensation reaction with fluorescein isothiocyanate (FITC) under alkaline conditions, and the intermediates obtained are directly hydrolyzed and demethylated in an alkaline aqueous solution to obtain the final products P1-P9;

[0027] Preferably, in step S6, the alkaline condition used in the condensation reaction is N,N-diisopropylethylamine (DIPEA), the solvent used is N,N-dimethylformamide (DMF), the reaction conditions are room temperature, nitrogen protection. The alkaline aqueous solution is a lithium hydroxide aqueous solution.

[0028] The present invention also provides a method for testing the binding ability of other compounds to the RORγ allosteric site using the fluorescent probe of formula (I), and the specific steps are as follows:

[0029] S1: mixing the RORγ small molecule fluorescent probe of formula (I), a protein containing a RORγ ligand binding domain and a test compound in a certain ratio to obtain a test system;

[0030] S2: Fluorescence polarization technology is used to measure the fluorescence polarization value of the test system through a multifunctional microplate reader, and whether the test compound can bind to the allosteric site of RORγ is determined based on the fluorescence polarization value.

[0031] Beneficial effects: Compared with the prior art, the compound provided by the present invention has fluorescent properties and has good specific binding to the allosteric binding site of the RORγ ligand binding domain. The compound is used as a small molecule fluorescent probe in fluorescence polarization technology, and the ligand screening and ligand affinity evaluation of the allosteric binding site of the RORγ ligand binding domain can be achieved through the competitive binding method, which provides a cheap, fast and stable activity test method for drug discovery and optimization targeting the allosteric binding site of the RORγ ligand binding domain. BRIEF DESCRIPTION OF THE DRAWINGS

[0032] Figure 1 This is a graph showing the change in fluorescence polarization signal of the fluorescent probe P8 as the concentration of protein RORγ-LBD changes.

[0033] Figure 2 P8 was used to test the reported RORγ allosteric inhibitors MRL003, MRL058, MRL871 and the RORγ orthosteric inhibitor GSK2981278 for their affinity to the RORγ allosteric site.

[0034] Figure 3 The results of the imaging experiment of the fluorescent probe P8 in the cell line A375 that highly expresses RORγ.

[0035] Figure 4 The results of the imaging experiment of the fluorescent probe P8 in wild-type 72hpf zebrafish.

[0036] Figure 5 For probe P8 1 H NMR spectra. DETAILED DESCRIPTION

[0037] The present invention is further described below in conjunction with examples. These examples are only used to illustrate the present invention and are not intended to limit the scope of the present invention. The experimental methods in the following examples that do not specify specific conditions are usually carried out according to conventional conditions in the art or according to the conditions recommended by the manufacturer; the raw materials, reagents, etc. used, unless otherwise specified, are all raw materials and reagents that can be obtained from commercial channels such as conventional markets. Any non-substantial changes and substitutions made by those skilled in the art on the basis of the present invention belong to the scope of protection claimed by the present invention.

[0038] Example 1 Synthesis of probe P1

[0039]

[0040] DMF (4 mL) was added to a mixture of AI-1 (400 mg, 0.75 mmol, 1.0 equiv.), N-Boc-1,6-hexanediamine (484.3 mg, 2.24 mmol, 3.0 equiv.), 1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium (109.5 mg, 0.15 mmol, 0.2 equiv.), and triethylamine (228.15 mg, 2.24 mmol, 3.0 equiv.). The reaction system gas was replaced with carbon monoxide three times, and the reaction was stirred at 80 ° C overnight. TLC detected that the reaction was complete, and water (5 mL) was added to the reaction to quench the reaction. The resulting mixture was filtered through a celite pad and extracted with ethyl acetate (3×20 mL). The combined organic layer was washed with saturated brine (5 mL) and dried over anhydrous magnesium sulfate. After filtration, the solvent was evaporated under reduced pressure and the residue was purified by silica gel column chromatography to obtain 252 mg of colorless transparent solid AI-2-L1; the yield was 48.2%. 1 H NMR(400MHz,Chloroform-d)δ9.00(s,1H),8.21-8.07(m,4H),7.91(d,J=8.2Hz,2H),7.75(t,J=7.8Hz,2H),7.64(t,J=8.0Hz,1H),6.65(s, 1H),4.58(s,1H),3.97(s,3H),3.56(q,J=6.7Hz,2H),3.17(d,J=5.8Hz,2H),1.72(q,J=7.3Hz,2H),1.61(s,8H),1.55(s,2H).MS(ESI):m / z calcd for C 35 H 36 ClF3N4O6[M+H] +=700.2275, found 700.2.

[0041] To a solution of AI-2-L1 (252 mg, 0.42 mmol, 1.0 equiv.) in dichloromethane (15 mL), trifluoroacetic acid (30 mL) was added and reacted at room temperature for 1.5 hours under nitrogen protection. The reaction was complete by TLC detection, and the solvent was evaporated under reduced pressure to obtain crude AI-3-L1, which was directly used in the next step without purification.

[0042] Dissolve the crude AI-3-L1 in anhydrous DMF (2 mL), add fluorescein isothiocyanate (85.6 mg, 0.22 mmol) and diisopropylethylamine (28.43 mg, 0.22 mmol). After the addition is complete, protect the reaction under nitrogen and react at room temperature overnight. TLC detects that the reaction is complete, quench the reaction mixture with water, and extract the reaction solution with ethyl acetate (3×10 mL). The combined organic layer is washed with saturated brine (5 mL) and dried over anhydrous magnesium sulfate. After filtration, evaporate the solvent to obtain the crude intermediate, dissolve the crude intermediate in THF (4.00 mL) solution, and add LiOH (24 mg, 1.0 mmol, 1.0 equiv.) aqueous solution (2 mL). Protect the reaction under nitrogen and avoid light for 3 hours. TLC detects that the reaction is complete, remove tetrahydrofuran under reduced pressure, and adjust the solution pH to 5-6. The mixture was extracted with ethyl acetate (3×10 mL), and the combined organic phases were purified by silica gel column chromatography to obtain the final product P1 as an orange-yellow solid (161.3 mg, 74.5%). 1 H NMR (500MHz, DMSO-d6) δ12.25(s,1H),10.45(s,1H),9.05(t,J=5.1Hz,1H),9.00(s,1H),8.40(s,1H),8.30(d ,J=8.4Hz,1H),8.11(d,J=8.4Hz,1H),8.04(d,J=7.9Hz,3H),8.00(d,J=8.0Hz,1H),7.94(d,J=7.9Hz,1H),7. 87(t,J=8.1Hz,1H),7.78(d,J=7.9Hz,2H),7.05(d,J=8.3Hz,1H),6.65(d,J=8.9Hz,2H),6.53(s,2H),6.46(d ,J=8.7Hz,2H),3.49(d,J=4.8Hz,2H),3.36(d,J=6.0Hz,2H),1.65-1.57(m,4H),1.41(s,4H).HRMS(ESI):m / z calcd.for C 50 H 37 ClF3N5O9S[M+H] +=975.1953,found974.2005.HPLC:t R =14.16 min, 95.74% purity.

[0043] Example 2 Synthesis of probe P2

[0044]

[0045] DMF (4 mL) was added to a mixture of AI-1 (300 mg, 0.56 mmol, 1.0 equiv.), N-Boc-1,7-heptanediamine (258 mg, 1.12 mmol, 2.0 equiv.), 1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium (82.1 mg, 0.11 mmol, 0.2 equiv.), and triethylamine (171.1 mg, 1.68 mmol, 3.0 equiv.). The reaction system gas was replaced with carbon monoxide three times, and the reaction was stirred at 80°C overnight. TLC detected that the reaction was complete, and the reaction mixture was quenched with water (5 mL), filtered through a diatomaceous earth pad, and the filtrate was extracted with ethyl acetate (3×10 mL). The combined organic layer was washed with saturated brine (10 mL) and dried over anhydrous magnesium sulfate. After filtration, the solvent was evaporated and the residue was purified by silica gel column chromatography to obtain 200 mg of colorless transparent solid AI-2-L2; the yield was 50.03%. 1 H NMR (400MHz, DMSO-d6) δ9.00 (s, 1H), 8.94 (t, J = 5.6Hz, 1H), 8.34 (d, J = 8.4Hz, 1H),8.13(d,J=8.3Hz,2H),8.11-8.09(m,1H),8.06(d,J=8.2Hz,1H),8.03(s, 1H),8.01-7.98(m,2H),6.74(s,1H),3.90(s,3H),3.35(s,2H),2.91(q,J=6.6 Hz,2H),1.59(s,2H),1.39(s,2H),1.36(s,9H),1.30-1.22(m,6H).MS(ESI)m / z calcd.forC 36 H 38 ClF3N4O6[M+H] + =714.2432, found 714.2.

[0046] To a DCM (15 mL) solution of AI-2-L2 (258.0 mg, 0.35 mmol, 1.0 equiv.), trifluoroacetic acid (3 mL) was added and reacted at room temperature for 1.5 hours under nitrogen protection. The reaction was complete by TLC detection, and the solvent was evaporated from the reaction mixture to obtain crude AI-3-L2, which was directly used in the next step without purification.

[0047] The crude product of AI-3-L2 was dissolved in anhydrous DMF (2 mL), and fluorescein isothiocyanate (107.00 mg, 0.22 mmol) and diisopropylethylamine (28.43 mg, 0.22 mmol) were added. After the addition was completed, the reaction was protected by nitrogen and the reaction was allowed to react overnight at room temperature. After water was added to the reaction mixture, the reaction solution was extracted with ethyl acetate (3×10 mL). The combined organic layer was washed with brine and dried over anhydrous magnesium sulfate. After filtration, the solvent was evaporated to obtain a crude product, which was dissolved in tetrahydrofuran (4 mL) and an aqueous solution (2 mL) of lithium hydroxide (24 mg, 1.0 mmol, 1.0 equiv.) was added. The reaction was protected by nitrogen and protected by light for 3 hours. After the reaction was complete by TLC, tetrahydrofuran was evaporated under reduced pressure and the pH of the solution was adjusted to 5-6. Ethyl acetate was used for extraction (3×10 mL), and the organic phases were combined and purified by silica gel column chromatography to obtain the final product P2 as an orange-yellow solid (87.1 mg, 56.6%). 1 H NMR (400MHz, DMSO-d6) δ12.01(s,1H),10.22(s,1H),8.99(d,J=5.8Hz,2H),8.37(s,1H),8.30(d,J=8.4Hz, 1H),8.09(dd,J=8.5,1.2Hz,1H),8.04(d,J=8.0Hz,3H),7.99(d,J=7.9Hz,1H),7.92(d,J=9.6Hz,1H),7.87( t,J=8.1Hz,1H),7.78(d,J=8.2Hz,2H),7.04(d,J=8.3Hz,1H),6.66(d,J=8.9Hz,2H),6.50(s,2H),6.44(d, J=8.9Hz,2H),3.48(d,J=5.0Hz,2H),3.35(q,J=6.5Hz,2H),1.66-1.55(m,4H),1.38(s,6H).HRMS(ESI):m / z calcd.forC 51 H 39 ClF3N5O9S[M+H] + =989.2109,found 988.2172.HPLC:t R =12.085min, 99.08% purity.

[0048] Example 3 Synthesis of probe P3

[0049]

[0050] To a mixture of AI-1 (300 mg, 0.56 mmol, 1.0 equiv.), N-Boc-1,8-octanediamine (242 mg, 1.12 mmol, 2.0 equiv.), 1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium (82.1 mg, 0.11 mmol, 0.2 equiv.), and triethylamine (171.1 mg, 1.68 mmol, 3.0 equiv.), N,N-dimethylformamide (4 mL) was added. The reaction system was replaced with carbon monoxide three times, and the reaction was stirred at 80 °C overnight. TLC detected that the reaction was complete, and the reaction mixture was quenched with water (10 mL) and filtered through a celite pad. The filtrate was extracted with ethyl acetate (3×10 mL). The combined organic layer was washed with saturated brine (10 mL) and dried over anhydrous magnesium sulfate. After filtration, the solvent was evaporated under reduced pressure and the residue was purified by silica gel column chromatography to obtain 270.0 mg of white solid AI-3-L3 with a yield of 66.21%. 1 H NMR (400MHz, DMSO) δ9.01 (s, 1H), 8.94 (t, J = 5.4Hz, 1H), 8.33 (d, J = 8.5Hz, 1H) ,8.11(t,J=6.4Hz,3H),8.05(d,J=8.1Hz,1H),8.03-7.95(m,3H),7.89(t,J=8 .0Hz,1H),6.72(s,1H),3.89(s,3H),3.34(s,2H),2.92-2.87(m,2H),1.64-1. 55(m,2H),1.39(s,2H),1.36(s,9H),1.25(dd,J=30.1,8.6Hz,8H).MS(ESI)m / z calcd.for C 37 H 40 ClF3N4O6[M+H] + =728.2588, found 728.2.

[0051] Trifluoroacetic acid (3 mL) was added to a solution of AI-3-L3 (200.0 mg, 0.28 mmol) in dichloromethane (15 mL), and the mixture was reacted at room temperature for 1.5 hours under nitrogen protection. The reaction was complete when detected by TLC, and the solvent was evaporated from the reaction mixture to obtain crude AI-3-L3.

[0052] The crude product of AI-3-L3 was dissolved in anhydrous DMF (2 mL), and fluorescein isothiocyanate (95.4 mg, 0.25 mmol) and diisopropylethylamine (57.64 mg, 0.45 mmol) were added. After the addition was completed, the reaction was protected by nitrogen and the reaction was allowed to react at room temperature overnight. The reaction mixture was quenched with water and extracted three times with ethyl acetate (10 mL). The combined organic layer was washed with saturated brine (10 mL) and dried over anhydrous magnesium sulfate. After filtration, the solvent was evaporated under reduced pressure to obtain a crude product, which was dissolved in THF (4 mL) and an aqueous solution (2 mL) of lithium hydroxide (24.0 mg, 1.0 mmol, 1.0 equiv.) was added. The reaction was protected by nitrogen and the reaction was allowed to react at room temperature for 3.0 hours. After the reaction was complete by TLC detection, tetrahydrofuran was evaporated under reduced pressure and the pH of the solution was adjusted to 5-6. The mixture was extracted with ethyl acetate (3×10 mL), and the combined organic phases were purified by silica gel column chromatography to obtain the final product P3 as an orange-yellow solid (41.8 mg, 30.1%). 1 H NMR (400MHz, DMSO-d6) δ11.94(s,1H),10.13(s,1H),8.98(s,2H),8.36(s,1H),8.30(d,J= 8.0Hz,1H),8.09(s,1H),8.04(d,J=7.6Hz,2H),8.00(d,J=7.9Hz,1H),7.93-7.86(m,1H), 7.78(d,J=7.6Hz,1H),7.04(d,J=8.1Hz,1H),6.66(d,J=8.6Hz,1H),6.48(s,1H),6.43(d, J=8.5Hz,1H),3.48(s,2H),3.34(s,2H),1.58(s,4H),1.29(d,J=45.8Hz,8H).MS(ESI): m / z calcd.for C 52 H 41 ClF3N5O9S[M+H] + =1003.2266,found 1002.2318.HPLC:t R =12.370 min, 99.05% purity.

[0053] Example 4 Synthesis of probe P4

[0054]

[0055] 1,4-Dioxane (20 mL) was added to a mixture of AI-1 (300.0 mg, 0.56 mmol, 1.0 equiv.), N-Boc-1,6-hexanediamine (241.1 mg, 1.12 mmol, 2.0 equiv.), palladium acetate (25.2 mg, 0.11 mmol, 0.2 equiv.), cesium carbonate (363.8 mg, 1.11 mmol, 2.0 equiv.), and 1,1'-binaphthyl-2,2'-bisdiphenylphosphine (69.6 mg, 0.11 mmol, 0.2 equiv.). The mixture was refluxed overnight under nitrogen protection. The reaction was complete after TLC detection. The reaction was quenched with water (10 mL), filtered through a celite pad, and the filtrate was extracted with ethyl acetate (3×10 mL). The combined organic layer was washed with saturated brine (10 mL) and dried over anhydrous magnesium sulfate. After filtration, the solvent was evaporated and the residue was purified by silica gel column chromatography to obtain white solid AI-2-L4 (203.0 mg, 54.1%). 1 H NMR(500MHz,DMSO-d6)δ8.06(d,J=8.4Hz,2H),8.00(d,J=8.1Hz,1H),7.95(d,J=8.0Hz,1H),7 .89(d,J=8.4Hz,2H),7.85-7.80(m,2H),7.55(d,J=1.5Hz,1H),6.93(dd,J=8.9,1.9Hz,1H),6 .79(t,J=5.5Hz,1H),6.74(t,J=5.0Hz,1H),3.87(s,3H),3.15(q,J=6.6Hz,2H),2.94-2.90(m ,2H),1.64(p,J=7.0Hz,2H),1.44-1.38(m,4H),1.37(s,9H),1.34-1.31(m,2H).MS(ESI):m / z calcd for C 34 H 36 ClF3N4O5[M+H] + =672.2, found 672.4.

[0056] To a solution of AI-2-L4 (203.0 mg, 0.3 mmol) in dichloromethane (15 mL), trifluoroacetic acid (3 mL) was added and the mixture was reacted at room temperature for 1.5 hours under nitrogen protection. The reaction was complete by TLC detection, and the solvent was evaporated under reduced pressure to obtain crude AI-3-L4. The compound was used directly in the next step without purification.

[0057] Dissolve the crude AI-3-L4 in anhydrous N,N-dimethylformamide (2 mL), add fluorescein isothiocyanate (79.0 mg, 0.2 mmol) and diisopropylethylamine (52.5 mg, 0.41 mmol). After the addition is complete, protect the reaction under nitrogen and react at room temperature overnight. After the reaction is quenched by adding water (10 mL), extract with ethyl acetate (3×20 mL). The combined organic layer is washed with saturated brine (10 mL) and dried over anhydrous magnesium sulfate. After filtration, the solvent is evaporated under reduced pressure to obtain the crude intermediate, which is dissolved in tetrahydrofuran (4 mL) and an aqueous solution (2 mL) of lithium hydroxide (24.0 mg, 1.0 mmol, 1.0 equiv.) is added. Protect the reaction under nitrogen and react at room temperature for 3.0 hours. After TLC detection, remove tetrahydrofuran under reduced pressure and adjust the pH of the solution to 5-6. The mixture was extracted with ethyl acetate (3×10 mL), and the combined organic phases were purified by silica gel column chromatography to give the final product P4 as an orange-yellow solid (51.1 mg, 41.2%). 1 H NMR (400MHz, DMSO-d6) δ11.68(s,1H),9.97(s,1H),8.20(s,1H),7.98(dd,J=7.9,4.5Hz,3H),7.94(d,J=8.0H z,1H),7.87(d,J=7.2Hz,1H),7.81(dd,J=10.5,8.9Hz,2H),7.66(d,J=8.2Hz,2H),6.95(d,J=8.3Hz,1H),6.92 (d,J=9.0Hz,1H),6.76(s,1H),6.70(d,J=9.1Hz,2H),6.20(d,J=9.5Hz,2H),6.17(s,2H),3.51(d,J=6.1Hz,2 H),3.17(d,J=3.1Hz,2H),1.64-1.59(m,2H),1.49(s,2H),1.43(d,J=6.6Hz,2H),1.24(s,2H).HRMS(ESI):m / z calcd.for C 49 H 37 ClF3N5O8S[M+H] + =947.2003,found 946.2001.HPLC:t R =12.384 min, 96.7% purity.

[0058] Example 5 Synthesis of probe P5

[0059]

[0060] 1,4-Dioxane (20 mL) was added to a mixture of AI-1 (400.0 mg, 0.75 mmol, 1.0 equiv.), N-Boc-1,7-heptanediamine (343.3 mg, 1.5 mmol, 2.0 equiv.), palladium acetate (33.6 mg, 0.15 mmol, 0.2 equiv.), cesium carbonate (489.00 mg, 1.50 mmol, 2.00 equiv.), and 1,1'-binaphthyl-2,2'-bisdiphenylphosphine (124.5 mg, 0.15 mmol, 0.2 equiv.). The mixture was refluxed overnight under nitrogen protection. The reaction was complete after TLC detection, and the reaction was quenched with water (15 mL), then filtered through a celite pad, and the filtrate was extracted with ethyl acetate (3×20 mL). The combined organic layer was washed with saturated brine (15 mL) and dried over anhydrous magnesium sulfate. After filtration, the solvent was evaporated under reduced pressure and the residue was purified by silica gel column chromatography to obtain white solid AI-2-L5 (200.0 mg, 46.6%). 1 H NMR (400MHz, DMSO-d6) δ8.07(d,J=8.5Hz,2H),8.00(d,J=8.1Hz,1H),7.95(d,J=7.9Hz,1H),7.89(d, J=8.5Hz,2H),7.84(d,J=8.7Hz,2H),7.55(d,J=1.8Hz,1H),6.93(dd,J=8.9,2.0Hz,1H),6.77-6.70(m ,2H),3.88(s,3H),3.16(q,J=6.7Hz,2H),2.91(d,J=6.0Hz,2H),1.64(p,J=7.0Hz,2H),1.53(dt,J=14 .6,7.1Hz,2H),1.41(s,2H),1.37(s,10H),1.30(d,J=5.0Hz,2H),1.26(d,J=3.8Hz,2H).MS(ESI):m / z calcd for C 35 H 38 ClF3N4O5[M+H] + =686.2, found 686.3.

[0061] To a solution of AI-2-L5 (240.0 mg, 0.35 mmol) in dichloromethane (15 mL), trifluoroacetic acid (3 mL) was added and the mixture was reacted for 1.5 hours under nitrogen protection. The reaction was complete by TLC detection, and the solvent was evaporated under reduced pressure from the reaction mixture to obtain crude AI-3-L5. The compound was directly used in the next step without purification.

[0062] The crude product of AI-3-L5 was dissolved in anhydrous N,N-dimethylformamide (2 mL), and fluorescein isothiocyanate (135.7 mg, 0.35 mmol) and diisopropylethylamine (90.04 mg, 0.70 mmol) were added. After the addition was completed, the reaction was protected by nitrogen and allowed to react overnight at room temperature. After the reaction was quenched by adding water (10 mL), it was extracted with ethyl acetate (3×20 mL). The combined organic layer was washed with saturated brine (15 mL) and dried over anhydrous magnesium sulfate. After filtration, the solvent was evaporated under reduced pressure to obtain the crude intermediate, which was dissolved in tetrahydrofuran (4 mL) and an aqueous solution (2 mL) of lithium hydroxide (24 mg, 1.0 mmol, 1.0 equiv.) was added. The reaction was protected by nitrogen and allowed to react at room temperature for 3.0 hours. After TLC detected that the reaction was complete, tetrahydrofuran was evaporated under reduced pressure and the pH of the solution was adjusted to 5-6. The mixture was extracted with ethyl acetate (3×10 mL), and the combined organic phases were purified by silica gel column chromatography to give the final product P5 as an orange-yellow solid (25.6 mg, 32.0%). 1 H NMR (400MHz, DMSO-d6) δ12.06(s,1H),10.28(s,1H),8.32(s,1H),7.99(d,J=8.0Hz,3H),7.94(d,J=8.1Hz,1H), 7.90(s,1H),7.81(t,J=8.4Hz,2H),7.66(d,J=6.7Hz,2H),7.55(s,1H),7.01(d,J=8.3Hz,1H),6.96(d,J=8.2Hz, 1H),6.91(d,J=8.7Hz,1H),6.71(s,1H),6.65(t,J=9.0Hz,2H),6.44(d,J=14.3Hz,2H),6.38(s,2H),3.48(s,2H) ,3.16(d,J=5.2Hz,2H),1.68(d,J=6.7Hz,2H),1.60(s,2H),1.46(s,2H),1.38(s,2H),1.24(s,2H).MS(ESI):m / z calcd.for C 50 H 39 ClF3N5O8S[M+H] + =961.2160,found961.0580.HPLC:t R =12.403min, 96.6% purity.

[0063] Example 6 Synthesis of probe P6

[0064]

[0065] 1,4-Dioxane (20 mL) was added to a mixture of AI-1 (400.0 mg, 0.75 mmol, 1.0 equiv.), N-Boc-1,8-octanediamine (365.2 mg, 1.5 mmol, 2.0 equiv.), palladium acetate (33.6 mg, 0.15 mmol, 0.2 equiv.), cesium carbonate (489.0 mg, 1.5 mmol, 2.0 equiv.), and 1,1'-binaphthyl-2,2'-bisdiphenylphosphine (124.5 mg, 0.15 mmol, 0.2 equiv.). The mixture was refluxed overnight under nitrogen protection. The reaction was complete after TLC detection, and the reaction was quenched by adding water (10 mL), then filtered through a celite pad, and extracted with ethyl acetate (3×15 mL). The combined organic layer was washed with saturated brine and dried over anhydrous magnesium sulfate. After filtration, the solvent was evaporated under reduced pressure and the residue was purified by silica gel column chromatography to obtain white solid AI-2-L6 (210.0 mg, 40.1%). 1 H NMR (400MHz, DMSO-d6) δ8.09-8.05(m,2H),8.00(d,J=8.1Hz,1H),7.95(d,J=7.9Hz,1H) ,7.91-7.87(m,2H),7.83(dd,J=8.6,7.2Hz,2H),7.54(d,J=2.0Hz,1H),6.93(dd,J=8.9 ,2.1Hz,1H),6.72(t,J=4.3Hz,2H),3.88(s,3H),3.15(q,J=6.6Hz,2H),2.90(q,J=6.5H z,2H),1.64(q,J=7.2Hz,2H),1.37(s,2H),1.37(s,9H),1.31-1.23(m,8H).MS(ESI):m / z calcd.for C 36 H 40 ClF3N4O5[M+H] + =700.2, found 700.2.

[0066] Trifluoroacetic acid (3 mL) was added to a solution of AI-2-L6 (210.0 mg, 0.3 mmol) in dichloromethane (15 mL), and the mixture was reacted for 1.5 hours under nitrogen protection. The reaction was complete by TLC detection, and the solvent was evaporated under reduced pressure to obtain crude AI-3-L6. The compound was directly used for the next step without purification.

[0067] Dissolve the crude AI-3-L6 in anhydrous N,N-dimethylformamide (2 mL), add fluorescein isothiocyanate (121.80 mg, 0.31 mmol) and diisopropylethylamine (80.8 mg, 0.63 mmol). After the addition is complete, protect the reaction under nitrogen and react at room temperature overnight. After the reaction mixture is quenched with water (10 mL), the reaction solution is extracted with ethyl acetate. The combined organic layer is washed with saturated brine (15 mL) and dried over anhydrous magnesium sulfate. After filtration, the solvent is evaporated under reduced pressure to obtain the crude intermediate, which is dissolved in tetrahydrofuran (4 mL) and an aqueous solution (2 mL) of lithium hydroxide (24.0 mg, 1.0 mmol, 1.0 equiv.) is added. Protect the reaction under nitrogen and protect the reaction for 3.0 hours. After the reaction is complete by TLC detection, tetrahydrofuran is evaporated under reduced pressure and the pH of the solution is adjusted to 5-6. The mixture was extracted with ethyl acetate (3×15 mL), and the combined organic phases were purified by silica gel column chromatography to obtain the final product P6 as an orange-yellow solid (71.0 mg, 40.0%). 1 H NMR (400MHz, DMSO-d6) δ11.98(s,1H),10.20(s,1H),8.30(s,1H),7.98(t,J=7.3Hz,3H),7.94(d,J=8.0Hz,1H),7.90( d,J=7.9Hz,1H),7.81(t,J=8.5Hz,2H),7.66(d,J=8.2Hz,2H),7.55(d,J=1.6Hz,1H),7.01(d,J=8.3Hz,1H),6.90(dd,J =9.0,1.8Hz,1H),6.70(s,1H),6.67(d,J=8.9Hz,2H),6.41(d,J=14.3Hz,2H),6.36(d,J=8.8Hz,2H),3.47(d,J=5.1Hz, 2H),3.19-3.12(m,2H),1.68-1.64(m,2H),1.59(d,J=6.5Hz,2H),1.45(s,2H),1.36(s,4H),1.24(s,2H).MS(ESI):m / z calcd.forC 51 H 41 ClF3N5O8S[M+H] + =975.2316,found 974.2340.HPLC:t R =13.014 min, 96.9% purity.

[0068] Example 7 Synthesis of probe P7

[0069]

[0070] To a mixture of AI-1 (300 mg, 0.56 mmol, 1.0 equiv.), N-Boc-2,2'-(ethylenedioxy)diethylamine (417.0 mg, 1.68 mmol, 3.0 equiv.), 1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium (82.1 mg, 0.11 mmol, 0.2 equiv.), and triethylamine (171.1 mg, 1.68 mmol, 3.0 equiv.), N,N-dimethylformamide (4 mL) was added. The reaction system was replaced with carbon monoxide three times, and the reaction was stirred at 80 ° C overnight. TLC detected that the reaction was complete, and water (10 mL) was added to the reaction to quench the reaction, and then filtered through a celite pad, and the filtrate was extracted with ethyl acetate (3×10 mL). The combined organic layer was washed with saturated brine (10 mL) and dried over anhydrous magnesium sulfate. After filtration, the solvent was evaporated under reduced pressure and the residue was purified by silica gel column chromatography to obtain 270.0 mg of white solid AI-2-L7 with a yield of 46.3%. 1 H NMR (500MHz, DMSO-d6) δ9.04 (dd, J=11.2, 5.5Hz, 2H), 8.35 (d, J=8.4Hz, 1H), 8.12 (dd, J=8. 4,2.0Hz,3H),8.06(d,J=8.1Hz,1H),8.01(dd,J=7.9,6.2Hz,3H),7.89(t,J=8.1Hz,1H),6.7 4(s,1H),3.89(s,3H),3.62(t,J=5.9Hz,2H),3.58(dd,J=5.7,3.4Hz,2H),3.52(dt,J=11.7 ,5.7Hz,4H),3.39(t,J=6.1Hz,2H),3.06(dd,J=11.6,5.8Hz,2H),1.35(s,9H).MS(ESI):m / z calcd.for C 37 H 40 ClF3N4O6[M+H] + =732.2, found 732.1.

[0071] Trifluoroacetic acid (3 mL) was added to a solution of AI-2-L7 (110.0 mg, 0.17 mmol) in dichloromethane (15 mL), and the mixture was reacted at room temperature for 1.5 hours under nitrogen protection. The reaction was complete after TLC detection, and the solvent was evaporated under reduced pressure to obtain crude AI-3-L7.

[0072] The crude product of AI-3-L7 was dissolved in anhydrous DMF (2 mL), and fluorescein isothiocyanate (75.0 mg, 0.19 mmol, 1.1 equiv.) and diisopropylethylamine (45.0 mg, 0.35 mmol, 2.0 equiv.) were added. After the addition was completed, the reaction mixture was protected by nitrogen and reacted at room temperature overnight. After TLC detected that the reaction was complete, the reaction mixture was quenched by adding water (10 mL), and then extracted with ethyl acetate (3×10 mL). The combined organic layer was washed with saturated brine (10 mL) and dried over anhydrous magnesium sulfate. After filtration, the filtrate was evaporated under reduced pressure to remove the solvent to obtain a crude product. The crude product was dissolved in tetrahydrofuran (4 mL), and an aqueous solution (2 mL) of lithium hydroxide (24 mg, 1.0 mmol, 1.0 equiv.) was added. The reaction was protected by nitrogen and reacted at room temperature for 3 hours. After TLC detected that the reaction was complete, tetrahydrofuran was evaporated under reduced pressure and the pH of the solution was adjusted to 5-6. The resulting mixture was extracted with ethyl acetate (3×10 mL), and the combined organic phases were purified by silica gel column chromatography to give the final product P7 as an orange-yellow solid (41.0 mg, 68.8%). 1 H NMR(400MHz,DMSO-d6)δ12.21(s,1H),10.31(s,1H),9.15(s,1H),9.02(s,1H),8.43(s,1H) ,8.31(d,J=8.4Hz,1H),8.12(d,J=8.6Hz,1H),8.08-8.02(m,2H),7.99(d,J=7.9Hz,1H),7.8 9(dt,J=16.0,8.0Hz,2H),7.79(d,J=7.9Hz,1H),7.07(d,J=8.3Hz,1H),6.67-6.57(m,3H),6 .50(d,J=8.7Hz,1H),3.65(d,J=6.0Hz,2H),3.56-3.48(m,2H),1.79(s,8H).HRMS(ESI):m / z calcd.forC 50 H 37 ClF3N5O9S[M+H] + =1007.1851,found 1006.1876.HPLC:t R =11.214 min, 96.4% purity.

[0073] Example 8 Synthesis of probe P8

[0074]

[0075] Add N,N-dimethylformamide (4 mL) to a mixture of AI-1 (300.0 mg, 0.56 mmol, 1.0 equiv.), (6-(3-aminopropionamido)hexyl)carbamic acid tert-butyl ester (482.5 mg, 1.68 mmol, 3.0 equiv.), 1,1'-bis[(diphenylphosphino)ferrocene]dichloropalladium (82.1 mg, 0.11 mmol, 0.2 equiv.), and triethylamine (171.1 mg, 1.68 mmol, 3.0 equiv.). Replace the gas in the reaction system with carbon monoxide three times, and stir at 80°C to react overnight. TLC detected that the reaction was complete. After the reaction mixture was quenched with water (10 mL), it was filtered through a celite pad, and the filtrate was extracted with ethyl acetate (3×10 mL). The combined organic layer was washed with saturated brine and dried over anhydrous magnesium sulfate. After filtration, the solvent was evaporated under reduced pressure and the residue was purified by silica gel column chromatography to obtain white solid AI-2-L8 (270.0 mg, 56.44%). 1 H NMR(400MHz, DMSO-d6)δ9.01(s,1H),8.96(t,J=5.6Hz,1H),8.34(d,J=8.4Hz,1H),8.15-8.09(m, 3H),8.06(d,J=8.0Hz,1H),8.04-7.98(m,3H),7.89(t,J=8.4Hz,1H),7.81(t,J=5.4Hz,1H),6.70 (s,1H),3.90(s,3H),3.11(q,J=7.0Hz,2H),3.04(q,J=6.1,5.6Hz,2H),3.03-2.96(m,2H),2.21( t,J=7.3Hz,2H),1.58(d,J=9.0Hz,2H),1.45-1.39(m,2H),1.36(s,9H),1.35(s,4H).MS(ESI):m / z calcd.for C 38 H 41 ClF3N5O7[M+H] + =771.2, found 771.0.

[0076] To a solution of AI-2-L8 (100.0 mg, 0.15 mmol) in dichloromethane (15 mL), trifluoroacetic acid (3 mL) was added and the mixture was reacted at room temperature for 1.5 hours under nitrogen protection. The reaction was complete by TLC detection, and the solvent was evaporated under reduced pressure to obtain crude AI-3-L8. The compound was used directly in the next step without purification.

[0077] Dissolve the crude AI-3-L8 in anhydrous N,N-dimethylformamide (2 mL), add fluorescein isothiocyanate (58.0 mg, 0.15 mmol) and diisopropylethylamine (38.50 mg, 0.30 mmol). After the addition is complete, protect the reaction under nitrogen and react at room temperature overnight. After the reaction mixture is quenched with water (5 mL), the reaction solution is extracted with ethyl acetate (3×10 mL). The combined organic layer is washed with saturated brine (10 mL) and dried over anhydrous magnesium sulfate. After filtration, the solvent is evaporated to obtain the crude intermediate, which is dissolved in tetrahydrofuran (4 mL) solution, and an aqueous solution (2 mL) of lithium hydroxide (24 mg, 1.0 mmol, 1.0 equiv.) is added. Protect the reaction under nitrogen and protect the reaction for 3 hours. After the reaction is complete by TLC detection, tetrahydrofuran is evaporated under reduced pressure and the pH of the solution is adjusted to 5-6. The mixture was extracted with ethyl acetate (3×10 mL), and the combined organic phases were purified by silica gel column chromatography to obtain the final product P8, which was an orange-yellow final product (30.2 mg, 38.0%). 1 H NMR (500MHz, DMSO-d6) δ12.35(s,1H),10.50(s,1H),9.00(s,1H),8.99(d,J=2.8Hz,1H),8.42(s,1H),8.31(d,J=8.4Hz, 1H),8.09(d,J=8.6Hz,1H),8.05(d,J=8.3Hz,2H),8.00(s,1H),7.93(d,J=8.4Hz,1H),7.91-7.84(m,1H),7.78(d,J=7.8 Hz,1H),7.08(d,J=8.3Hz,1H),6.60(d,J=8.5Hz,3H),6.50(d,J=8.9Hz,2H),3.65(d,J=4.7Hz,2H),3.33(d,J=6.3Hz,2H ),3.07(d,J=6.0Hz,2H),2.42(t,J=7.2Hz,2H),1.58(d,J=6.6Hz,2H),1.45(d,J=6.6Hz,2H),1.35(s,4H),1.24(s,2H).( Figure 4 )HRMS(ESI):m / zcalcd.for C 53 H 42 ClF3N6O 10 S[M+H] + =1046.2324,found 1045.2350.HPLC:t R =11.162min, 95.7% purity.

[0078] Example 9 Synthesis of probe P9

[0079]

[0080] 1,4-Dioxane (20.0 mL) was added to a mixture of AI-1 (375.2 mg, 0.7 mmol, 1.2 equiv.), oct-7-yn-1-amine (148.8 mg, 0.6 mmol, 1.0 equiv.), palladium acetate (10.8 mg, 0.05 mmol, 0.04 equiv.), cuprous iodide (9.1 mg, 0.05 mmol, 0.04 equiv.), and triphenylphosphine (37.6 mg, 0.14 mmol, 0.12 equiv.). The system was protected with nitrogen and refluxed overnight. TLC detected that the reaction was complete, and the reaction mixture was quenched with water (10 mL), filtered through a celite pad, and the filtrate was extracted with ethyl acetate (3×20 mL). The combined organic layer was washed with saturated brine (10 mL) and dried over anhydrous magnesium sulfate. After filtration, the solvent was evaporated and the residue was purified by silica gel column chromatography to obtain white solid AI-2-L9 (250.0 mg, 46.9%). 1 H NMR (400MHz, DMSO-d6) δ8.49(d,J=5.0Hz,1H),8.23(d,J=8.4Hz,1H),8.12(d,J=2.2Hz,1H),8.10(d,J=2.2Hz, 1H),8.05(d,J=8.1Hz,1H),8.02(s,1H),7.99-7.95(m,2H),7.89(t,J=7.7Hz,1H),7.70(s,2H),7.64(dd,J=8. 4,1.3Hz,1H),3.89(d,J=1.1Hz,3H),2.85-2.76(m,2H),2.54(dd,J=13.8,6.8Hz,2H),1.63(dt,J=17.0,8.1Hz ,2H),1.58-1.51(m,2H),1.52-1.44(m,2H),1.40(dd,J=15.1,8.0Hz,2H),1.32(d,J=14.6Hz,2H).MS(ESI)m / z calcd.for C 39 H 29 ClF3N3O5[M+H] + =711.2,found711.0.

[0081] To a solution of AI-2-L9 (270.0 mg, 0.38 mmol) in N,N-dimethylformamide (2 mL), add fluorescein isothiocyanate (67.0 mg, 0.17 mmol) and diisopropylethylamine (44.3 mg, 0.34 mmol). After the addition is complete, protect the reaction mixture with nitrogen and react overnight at room temperature. After the reaction mixture is quenched with water (10 mL), it is extracted with ethyl acetate (3×20 mL). The combined organic layer is washed with saturated brine and dried over anhydrous magnesium sulfate. After filtration, the solvent is evaporated to obtain a crude product, which is dissolved in tetrahydrofuran (4 mL) solution, and an aqueous solution (2 mL) of lithium hydroxide (24 mg, 1.0 mmol, 1.0 equiv.) is added. Protect the reaction mixture with nitrogen and react at room temperature for 3.0 hours. After the reaction is complete by TLC, tetrahydrofuran is evaporated under reduced pressure and the pH of the solution is adjusted to 5-6. The mixture was extracted with ethyl acetate (3×20 mL), and the combined organic phases were purified by silica gel column chromatography to give the final product P9 as an orange-yellow solid (38.4 mg, 31.1%). 1 H NMR (400MHz, DMSO-d6) δ11.42(s,1H),9.74(s,1H),8.49(s,1H),8.18(d,J=8.4Hz,1H),8.08(s,1H),8.04( d,J=8.0Hz,1H),7.99(d,J=7.6Hz,3H),7.88(d,J=7.8Hz,1H),7.80(d,J=8.1Hz,1H),7.72(d,J=8.0Hz,2H), 7.63(dd,J=8.4,1.5Hz,1H),6.90(d,J=8.2Hz,1H),6.67(d,J=9.2Hz,3H),6.05(d,J=9.1Hz,2H),5.97(s,2 H),2.56(d,J=7.1Hz,2H),2.03-1.98(m,2H),1.52(s,2H),1.42(d,J=7.3Hz,2H).HRMS(ESI):m / zcalcd.for C 51 H 41 ClF3N5O8S[M+H] + =956.1894,found 955.1955.HPLC:t R =8.524min, 96.3% purity.

[0082] Example 10 Optical and biological experiments of some compounds of the present invention

[0083] 1) Optical properties of fluorescent probes in Tris buffer solution

[0084] The fluorescent probes P1 to P9 prepared in the above Examples 1 to 9 were diluted from the mother solution (10 mM) to 100 μM using a Tris buffer solution (20 mM Tris, 150 mM NaCl, 5 mM DTT, pH = 8). Using a multifunctional microplate reader (SpectraMax M5), the excitation wavelength was set to 490 nm, and the corresponding fluorescence excitation intensity of the probe to be tested in the range of 410 to 516 nm was scanned to obtain the fluorescence excitation spectrum of the probe. Using a multifunctional microplate reader (SpectraMax M5), the emission wavelength was set to 525 nm, and the corresponding fluorescence emission intensity values ​​of the probe to be tested at 490 to 624 nm were scanned to obtain the fluorescence emission spectrum of the probe. 1 μM fluorescein was prepared with water, and the integrated fluorescence intensity of 1 μM fluorescein and the maximum absorbance value at the excitation wavelength (490 nm) were detected. The integrated fluorescence intensity of 100 μM fluorescent probe and the maximum absorbance value at the excitation wavelength (490 nm) were detected. Substitute the obtained parameters into the quantum yield calculation formula to calculate the fluorescence quantum yield of the fluorescent probe solution. The calculation formula is:

[0085]

[0086] Where Y U is the quantum yield of the unknown sample to be measured; Y S is the fluorescence quantum yield of the standard substance; F U 、F S A is the integrated fluorescence intensity of the sample to be tested and the dilute solution of the standard; U , A S It is the maximum absorbance value of the sample and standard at the excitation wavelength.

[0087] The experimental results are shown in Table 1. The small molecule fluorescent probes described in the present invention can all emit fluorescence under the irradiation of excitation light, and the maximum emission wavelength is about 520 nM. Some probes such as P1 and P8 have a higher fluorescence quantum yield.

[0088] Table 1 Maximum excitation and emission wavelengths and fluorescence quantum yields of the fluorescent probes of the present invention

[0089]

[0090]

[0091] 2) Detection of the affinity of the probe to RORγ-LBD by surface plasmon resonance

[0092] The RORγ-LBD (aa261-518) protein was dissolved in PBS buffer solution (pH = 8, 150mM NaCl, 0.05% tween-20). After activating the carboxyl groups on the surface of the SPR chip (CM5) with EDC (40mg / mL), the RORγ-LBD protein was fixed on the SR7000 GOLD SENSOR SLIDE sensor chip (CM5, Biacore). After the protein was fixed, the chip was blocked with NHS (5mg / mL). The RORγ-LBD protein was incubated with different concentrations of fluorescent probes (250, 125, 62.5, 31.25, 15.625, 7.81, 3.91, 1.95, 0.977, 0.488μM) in PBS (1X) buffer containing 5% DMSO and 0.05% tween20. The signal was recorded and analyzed using a Reichert4SPR instrument.

[0093] The experimental results are shown in Table 2. All nine fluorescent probes described in the present invention can bind to RORγ-LBD. Probes P1, P2, P3, and P8 have good affinity for RORγ-LBD.

[0094] Table 2 Surface plasmon resonance detection of the affinity of the fluorescent probe of the present invention to RORγ-LBD

[0095] Compound <![CDATA[K d a ]]> P1 B P2 B P3 B P4 C P5 C P6 C P7 C P8 A P9 C

[0096] a A: less than 1 μM; B: 1 μM to 10 μM; C: greater than 10 μM and less than 100 μM.

[0097] Example 11 Testing the affinity of compounds for the RORγ allosteric site using fluorescence polarization technology and fluorescent probe P8

[0098] Fluorescence polarization (FP) is a phenomenon in which the light emitted by a fluorescent molecule has unequal intensities along different polarization axes. This phenomenon is currently widely used to detect the binding of macromolecules to small molecules, and has the advantages of being fast, stable, and cheap (Methods Appl. Fluoresc. 2016, 4, 022001). In the present invention, when the fluorescent probe binds to the RORγ-LBD protein, its fluorescence polarization signal, millipolarization units (mP) will increase compared to when not bound. At this point, adding a test compound that competes with the fluorescent probe for binding to the RORγ-LBD allosteric site to the system will cause mP to decrease, and the affinity of the test compound to RORγ-LBD will be judged according to the degree of decrease.

[0099] The following is an example of using probe P8 as a fluorescent probe to test the inhibitory activity of a compound on the RORγ allosteric site:

[0100] 1) Test the probe-protein curve to determine the optimal protein working concentration

[0101] Add 20 μL of fluorescent probe P8 (final concentration 100 nM), 20 μL of Tris buffer solution (20 mM Tris, 150 mM NaCl PH = 8.0, 0.05% Tween-20) and 20 μL of RORγ-LBD (aa261-518) protein to the test wells of a 384-well black board (#3575, Corning). The final working concentration of RORγ-LBD protein was diluted 1.5 times from 100 nM, and 3 replicate wells were set for each concentration, for a total of 13 concentration gradients. After addition, incubate at 4°C for 0.5 hours. Subsequently, the mP value of each well was read using the fluorescence polarization module (ex: 490 nm, em: 525 nm) of a multifunctional microplate reader (SpectraMax M5), and the data was curve fitted and analyzed using Graph pad Prism 7.0 ( Figure 1 ). The experimental results showed that when the concentration of RORγ-LBD protein was 60 nM, the fluorescence polarization signal reached the upper platform, so 60 nM was selected as the working concentration of RORγ-LBD protein.

[0102] 2) Using probe P8 to test the affinity of the compound to the RORγ-LBD allosteric site

[0103] This example tests the reported RORγ allosteric inhibitors MRL003, MRL058, MRL871 and the RORγ orthosteric inhibitor GSK2981278, and verifies the reliability of this method by comparing the activity tested by this method with the activity reported in the literature.

[0104] Add 20 μL of fluorescent probe P8 (final concentration 100 nM), 20 μL of RORγ-LBD (final concentration 60 nM) protein and 20 μL of the test compound of the corresponding concentration to the test wells of the 384-well black board (#3575, Corning). The concentration of MRL-003 was diluted twice from 33 μM to 1.52 nM, and the test concentrations of MRL-058, MRL871 and GSK2981278 were diluted three times from 10 μM to 0.057 nM, and three replicate wells were set for each concentration. After the addition was completed, incubate at 4°C for 0.5 hours, and then use the fluorescence polarization module (ex: 490 nm, em: 525 nm) of the multifunctional microplate reader (SpectraMax M5) to read the mP value of each well, and the data was curve fitted using Graphpad Prism 7.0 to calculate the IC of each compound. 50value( Figure 2 ). The experimental results showed that the IC 50 They are 3635.0nM, 90.8nM, and 2.0nM, respectively. The results are similar to the activity data reported for these three compounds, which shows that the activity test method using the fluorescent probe P8 of the present invention can better verify whether the compound has RORγ-LBD allosteric site affinity. At the same time, the reported positive drug GSK2981278 targeting the orthosteric site of the RORγ ligand binding domain did not detect activity using this activity detection method, which shows that the activity test method using the fluorescent probe P8 of the present invention will not be affected by RORγ orthosteric inhibitors.

[0105] Example 12: Imaging of RORγ-overexpressing cells using fluorescent probe P8

[0106] A375 cells with high expression of RORγ were selected for imaging experiments. A375 cells were inoculated in a 6-well plate and divided into two groups: a probe group and a positive drug probe group, with three replicates in each group. The positive drug probe group was incubated overnight with 25 μM of the positive compound MRL871, and the probe group was not treated. The next day, the culture medium was aspirated, each well was washed with PBS (3×1 mL), and then 4% paraformaldehyde fixative (1 mL, P0099, Beyotime) was added to fix at room temperature for 15 minutes. Subsequently, the fixative was aspirated, and after washing with PBS (3×1 mL), a probe P8 (1 mL) with a final concentration of 10 μM was added to each well and incubated at room temperature for 30 minutes. Subsequently, the probe solution was aspirated, washed with PBS (3×1 mL), and a small amount of DAPI nuclear staining solution (C1005, Beyotime) that could cover the bottom of the well was added to stain at room temperature for 3-5 minutes. After staining, the staining solution was discarded, and the cells were washed with PBS (3×1 mL). The fluorescence imaging results were observed and recorded under a Zeiss LSM 800 (Carl Zeiss, Germany) fluorescence inverted microscope. The relevant fluorescence parameters were: FITC (Ex: 494 nm / Em: 518 nm), DAPI (Ex: 359 nm / Em: 461 nm). Figure 3 ) As shown in the results, P8, as a RORγ-specific green fluorescent probe, can clearly stain A375 cells that highly express RORγ. In addition, in the positive drug probe group, the fluorescence intensity of A375 cells treated with the RORγ allosteric inhibitor MRL871 was significantly lower than that of the probe group, which also shows that the fluorescent probe P8 has good specificity in the imaging experiment.

[0107] Example 13: Fluorescent probe P8 for zebrafish in vivo imaging

[0108] AB wild-type zebrafish embryos were collected and raised in a light incubator for 72 hours. The zebrafish were then placed in a 6-well plate and randomly divided into three groups: a blank control group, a probe group, and a positive drug probe group. There were 20 zebrafish fry in each well, and three parallel groups were set up. Subsequently, the probe P8 with a final concentration of 10 μM was added to the probe group, and the probe P8 with a final concentration of 10 μM and the positive compound MRL871 with a final concentration of 25 μM were added to the positive drug probe group at the same time. The blank control group was not treated. After incubation at room temperature in the dark for 30 minutes, the solution in each well was discarded and washed three times with PBS. The zebrafish in each well were selected and observed under a stereofluorescence microscope (Leica DFC17000T) and the imaging results were recorded. The experimental results are shown in the figure. Figure 4 As shown in the figure, in zebrafish at 72hpf, the expression of RORγ is mainly concentrated in the liver, intestine and other organs, and significant green fluorescence is emitted in the zebrafish intestine in the probe group. In addition, the green fluorescence is significantly reduced in the zebrafish intestine incubated with P8 and MRL871. This indicates that the RORγ allosteric inhibitor MRL871 can compete with the fluorescent probe P8 for binding, which is consistent with the results of the cell imaging experiment, and also shows that the probe P8 has good RORγ specificity.

Claims

1. A novel small molecule fluorescent probe targeting RORγ, comprising a compound of the following general formula (I) or a pharmaceutically acceptable salt thereof: In the general formula (I): L stands for L1 2. The method for preparing the novel small molecule fluorescent probe targeting RORγ according to claim 1, characterized in that: The following steps are involved: S1: reacting the raw material AI-1 with carbon monoxide and different diamine compounds under the catalytic conditions of base and catalyst to obtain the intermediate AI-2-L 1~3,7,8 ; S2: The raw material AI-1 is coupled with a diamine compound using a Buchwald-Hartwig reaction under the conditions of a base, a catalyst, and a ligand to obtain the intermediate AI-2-L 4~6 ; S3: The raw material AI-1 and 2-(7-octyne-1-yl)-1H-isoindole-1,3-dione are coupled by Sonogashira reaction under base and catalyst conditions to obtain intermediate AI-L9; S4: Raw material AI-2-L 1~8 Dissolve in dichloromethane and react at room temperature under acidic conditions to remove the tert-butyloxycarbonyl group Boc to obtain compound AI-3-L 1~8 ; S5: Reverse the reaction of intermediate AI-2-L9 with hydrazine hydrate in ethanol to remove the protecting group and obtain compound AI-3-L9; S6: Intermediate AI-3-L 1~9 The intermediate is directly hydrolyzed and demethylated in an alkaline aqueous solution to obtain the final products P1 to P9. In step S1, the diamine compound is a mono-tert-butyloxycarbonyl Boc-protected diamine; the carbon monoxide pressure used is 1 to 3 atmospheres; the organic solvent of the reaction is one or more of N,N-dimethylformamide, 1,4-dioxane or tetrahydrofuran; the base selected for the reaction is one or more of N,N-diisopropylethylamine or triethylamine; the catalyst selected for the reaction is one or more of 1,1'-bis(diphenylphosphino)ferrocenepalladium dichloride, palladium acetate or tetrakistriphenylphosphine palladium; the reaction temperature is 80-120°C; In step S2, the Buchwald-Hartwig reaction is carried out using a catalyst of Pd2(dba)3, Pd(OAc)2 or Pd(Dppf)Cl2; a base of one or more of N,N-diisopropylethylamine, triethylamine, cesium carbonate, potassium tert-butoxide or sodium tert-butoxide; a ligand of 2-dicyclohexylphospho-2',4',6'-triisopropylbiphenyl or 1,1'-binaphthyl-2,2'-bisdiphenylphosphine, and a solvent of 1,4-dioxane; In step S3, the catalyst used in the Sonogashira reaction is Pd2(dba)3, Pd(OAc)2, Pd(dppf)Cl2 or CuI, and the organic solvent used is one or more of N,N-diisopropylethylamine or triethylamine; In step S4, the acidic reagent is trifluoroacetic acid or dioxane hydrochloride solution; In step S6, the alkaline condition used for the condensation reaction is N,N-diisopropylethylamine; the solvent used is N,N-dimethylformamide; the reaction conditions are room temperature and nitrogen protection; and the alkaline aqueous solution is lithium hydroxide aqueous solution.

3. Use of the small molecule fluorescent probe according to claim 1 in the preparation of cell imaging or in vivo imaging probes; The small molecule fluorescent probe is the following compound: